Compare BLTE & GTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | GTLB |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.5B |
| IPO Year | 2021 | 2021 |
| Metric | BLTE | GTLB |
|---|---|---|
| Price | $173.05 | $47.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 27 |
| Target Price | ★ $198.00 | $37.17 |
| AVG Volume (30 Days) | 198.1K | ★ 5.5M |
| Earning Date | 05-08-2026 | 06-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $955,224,000.00 |
| Revenue This Year | N/A | $18.72 |
| Revenue Next Year | $492.11 | $16.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 25.81 |
| 52 Week Low | $65.00 | $18.73 |
| 52 Week High | $200.00 | $55.55 |
| Indicator | BLTE | GTLB |
|---|---|---|
| Relative Strength Index (RSI) | 54.90 | 62.42 |
| Support Level | $167.80 | $36.50 |
| Resistance Level | $182.61 | $55.55 |
| Average True Range (ATR) | 7.90 | 2.17 |
| MACD | 2.18 | -0.04 |
| Stochastic Oscillator | 48.43 | 47.18 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
GitLab Inc operates on an all-remote model. GitLab is a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation, following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, & the Asia Pacific. It focused on accelerating innovation & broadening the distribution of its platform to companies across the world.